logo

XTLB

Xtl Biopharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

XTLB fundamentals

Xtl Biopharmaceuticals (XTLB) released its earnings on Dec 30, 2024: revenue was -- (YoY 0.00%), beat estimates; EPS was -- (YoY 0.00%), met estimates.
Revenue / YoY
--
0.00%
EPS / YoY
--
0.00%
Report date
Dec 30, 2024
EPS
Revenue

Revenue & Expenses

XTLB has released its 2024 Q4 earnings report, with revenue of 289.00K, reflecting a YoY change of NaN%, and net profit of -255.00K, showing a YoY change of 10.21%. The Sankey diagram below clearly presents XTLB's revenue sources and cost distribution.

Key Indicators

Xtl Biopharmaceuticals (XTLB) key financial stats and ratios, covering profitability, financial health, and leverage.
Xtl Biopharmaceuticals (XTLB)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Xtl Biopharmaceuticals (XTLB)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Xtl Biopharmaceuticals (XTLB)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Xtl Biopharmaceuticals (XTLB) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Xtl Biopharmaceuticals (XTLB) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield